Skip to main content

Advertisement

Table 1 Monoclonal Antibodies in Clinical Trials

From: Biochemical prevention and treatment of viral infections – A new paradigm in medicine for infectious diseases

Product Company Disease Status
MEDI-501 MedImmune Genital Warts HPV II
Nabi-HB Nabi Biopharmaceuticals Hepatitis B Market
Ostavir Protein Design Labs Hepatitis B II
XTL-002 XTL Biopharmaceuticals Ltd. Hepatitis C I
Civacir Nabi Biopharmaceuticals Hepatitis C I/II
1F7 Antibody Immune Network Ltd. Hepatitis C, HIV/AIDS Preclinical
PRO 140 Progenics Pharmaceuticals HIV/AIDS Preclinical
hNM01 AbNovo Inc., Immune Network Ltd. HIV/AIDS I
PRO 367 Roche Holding Progenics Pharmaceuticals HIV/AIDS I/II
TNX-355 Tanox, Inc., Biogen, Inc. (Massachusetts) HIV/AIDS I
OraQuick HIV-1 OraSure Technologies, Inc. HIV/AIDS Market
Cytolin CytoDyn Amerimmune Pharmaceuticals, Inc. HIV/AIDS I/II
Tipranavir TIPRANAVIR HIV/AIDS III
HXB AAI International, AnaaiPharma Company Herpes Simplex Virus type 2 Preclinical
MEDI-491 MedImmune Human B19 parvovirus I
Synagis™ (Palivizumab) MedImmune Respiratory Syncytial Virus Approved in 1998
Numax MedImmune Respiratory Syncytial Virus Preclinical
INS37217 Intranasal Inspire Pharmaceuticals Rhinovirus (common cold) II